Literature DB >> 24912948

Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions.

Tai Hato1, Lipika Goyal, Tim F Greten, Dan G Duda, Andrew X Zhu.   

Abstract

Immune checkpoint blockade has recently emerged as a promising therapeutic approach for various malignancies including hepatocellular carcinoma (HCC). Preclinical and clinical studies have shown the potential benefit of modulating the immunogenicity of HCC. In addition, recent advances in tumor immunology have broadened our understanding of the complex mechanism of immune evasion. In this review we summarize the current knowledge on HCC immunology and discuss the potential of immune checkpoint blockade as a novel HCC therapy from the basic, translational, and clinical perspectives.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24912948      PMCID： PMC4211962          DOI： 10.1002/hep.27246

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


  62 in total

1.  CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice.

Authors:  E A Tivol; S D Boyd; S McKeon; F Borriello; P Nickerson; T B Strom; A H Sharpe
Journal:  J Immunol       Date:  1997-06-01       Impact factor: 5.422

2.  Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma.

Authors:  Lars A Ormandy; Tina Hillemann; Heiner Wedemeyer; Michael P Manns; Tim F Greten; Firouzeh Korangy
Journal:  Cancer Res       Date:  2005-03-15       Impact factor: 12.701

3.  Analysis of CD4+ T-Cell responses to a novel alpha-fetoprotein-derived epitope in hepatocellular carcinoma patients.

Authors:  Akeel Alisa; Annette Ives; Ansar A Pathan; Cristina V Navarrete; Roger Williams; Antonio Bertoletti; Shahriar Behboudi
Journal:  Clin Cancer Res       Date:  2005-09-15       Impact factor: 12.531

4.  Integration of CD28 and CTLA-4 function results in differential responses of T cells to CD80 and CD86.

Authors:  Claire N Manzotti; Michael K P Liu; Fiona Burke; Laure Dussably; Yong Zheng; David M Sansom
Journal:  Eur J Immunol       Date:  2006-06       Impact factor: 5.532

5.  Restoring function in exhausted CD8 T cells during chronic viral infection.

Authors:  Daniel L Barber; E John Wherry; David Masopust; Baogong Zhu; James P Allison; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Nature       Date:  2005-12-28       Impact factor: 49.962

6.  Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma.

Authors:  K Ohnishi; H Yoshioka; S Ito; K Fujiwara
Journal:  Hepatology       Date:  1998-01       Impact factor: 17.425

7.  Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.

Authors:  Firouzeh Korangy; Lars A Ormandy; Jörg S Bleck; Jürgen Klempnauer; Ludwig Wilkens; Michael P Manns; Tim F Greten
Journal:  Clin Cancer Res       Date:  2004-07-01       Impact factor: 12.531

8.  Percutaneous ethanol injection therapy for hepatocellular carcinoma. A histopathologic study.

Authors:  S Shiina; K Tagawa; T Unuma; R Takanashi; K Yoshiura; Y Komatsu; Y Hata; Y Niwa; Y Shiratori; A Terano
Journal:  Cancer       Date:  1991-10-01       Impact factor: 6.860

9.  FOXP3 controls regulatory T cell function through cooperation with NFAT.

Authors:  Yongqing Wu; Madhuri Borde; Vigo Heissmeyer; Markus Feuerer; Ariya D Lapan; James C Stroud; Darren L Bates; Liang Guo; Aidong Han; Steven F Ziegler; Diane Mathis; Christophe Benoist; Lin Chen; Anjana Rao
Journal:  Cell       Date:  2006-07-28       Impact factor: 41.582

10.  Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) T cells.

Authors:  W Chen; W Jin; S M Wahl
Journal:  J Exp Med       Date:  1998-11-16       Impact factor: 14.307
View more
  100 in total

Review 1.  Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches.

Authors:  Tim F Greten; Xin W Wang; Firouzeh Korangy
Journal:  Gut       Date:  2015-02-09       Impact factor: 23.059

Review 2.  High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy.

Authors:  Suresh Gopi Kalathil; Yasmin Thanavala
Journal:  Cancer Immunol Immunother       Date:  2016-02-24       Impact factor: 6.968

3.  Immune play: defending the liver.

Authors:  Geraldine O'Sullivan Coyne; Tim F Greten
Journal:  Hepat Oncol       Date:  2015-01-12

4.  Host antitumor resistance improved by the macrophage polarization in a chimera model of patients with HCC.

Authors:  Akira Asai; Yusuke Tsuchimoto; Hideko Ohama; Shinya Fukunishi; Yasuhiro Tsuda; Makiko Kobayashi; Kazuhide Higuchi; Fujio Suzuki
Journal:  Oncoimmunology       Date:  2017-03-03       Impact factor: 8.110

Review 5.  Current status and perspectives of immune-based therapies for hepatocellular carcinoma.

Authors:  Maridi Aerts; Daphné Benteyn; Hans Van Vlierberghe; Kris Thielemans; Hendrik Reynaert
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 6.  Immune checkpoint inhibitors for hepatocellular carcinoma.

Authors:  Christopher E Jensen; Arturo Loaiza-Bonilla; Paula A Bonilla-Reyes
Journal:  Hepat Oncol       Date:  2016-06-27

7.  A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma.

Authors:  Qunfeng Wu; Liya Pi; Thu Le Trinh; Chaohui Zuo; Man Xia; Yu Jiao; Zhouhua Hou; Sung Jo; William Puszyk; Kien Pham; David R Nelson; Keith Robertson; David Ostrov; Pranela Rameshwar; Chang Qing Xia; Chen Liu
Journal:  Mol Ther       Date:  2017-08-10       Impact factor: 11.454

8.  Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.

Authors:  Kohei Shigeta; Meenal Datta; Tai Hato; Shuji Kitahara; Ivy X Chen; Aya Matsui; Hiroto Kikuchi; Emilie Mamessier; Shuichi Aoki; Rakesh R Ramjiawan; Hiroki Ochiai; Nabeel Bardeesy; Peigen Huang; Mark Cobbold; Andrew X Zhu; Rakesh K Jain; Dan G Duda
Journal:  Hepatology       Date:  2019-10-14       Impact factor: 17.425

9.  Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma.

Authors:  Qian-Kun Xie; Yu-Jie Zhao; Tao Pan; Ning Lyu; Lu-Wen Mu; Shao-Long Li; Mu-De Shi; Zhen-Feng Zhang; Peng-Hui Zhou; Ming Zhao
Journal:  Oncoimmunology       Date:  2016-05-13       Impact factor: 8.110

10.  Liver Tumor Microenvironment.

Authors:  Diamantis I Tsilimigras; Ioannis Ntanasis-Stathopoulos; Dimitrios Moris; Timothy M Pawlik
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.